NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $9,400,000 | -0.3% | 54,302 | -19.8% | 1.30% | -25.5% |
| Q3 2020 | $9,429,000 | +37.2% | 67,687 | +17.7% | 1.75% | +24.6% |
| Q2 2020 | $6,871,000 | +39.0% | 57,509 | +16.3% | 1.40% | -14.2% |
| Q1 2020 | $4,944,000 | +35.8% | 49,454 | +59.7% | 1.63% | +68.9% |
| Q4 2019 | $3,641,000 | +192.9% | 30,974 | +114.3% | 0.97% | +138.5% |
| Q3 2019 | $1,243,000 | +48.2% | 14,455 | +7.8% | 0.40% | +36.4% |
| Q1 2019 | $839,000 | -68.1% | 13,415 | -55.8% | 0.30% | -76.7% |
| Q1 2018 | $2,632,000 | +157.3% | 30,370 | +169.8% | 1.27% | +98.4% |
| Q3 2017 | $1,023,000 | +83.0% | 11,255 | +88.7% | 0.64% | -19.9% |
| Q1 2017 | $559,000 | -37.5% | 5,965 | -30.4% | 0.80% | -29.3% |
| Q3 2016 | $895,000 | +21.8% | 8,570 | -14.0% | 1.13% | +2.1% |
| Q2 2016 | $735,000 | -34.5% | 9,960 | -40.1% | 1.11% | -5.9% |
| Q4 2015 | $1,122,000 | – | 16,618 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |